BioSpace News Archive

Myomo to Attend with Ryzur Medical to Assess Chinese Market Opportunity

Dr. Grunstein brings more than 15 years of expertise in partnering, acquisitions and licensing in the biopharmaceutical industry and will lead strategic partnering to enhance the development of Xencor’s pipeline of drug candidates.

Adjusted EBITDA for the nine-month period ended March 31, 2019 increased by 94%. Management expects to exceed guidance of $38 million for fiscal year ending June 30, 2019.

Announced it has committed to an expansion of its clinical and drug safety portfolio, revealing new initiatives.

More residency training positions needed

First-of-its-kind study seeking to evaluate the potential anti-tumor effect of the IL-12, IDO1 and anti-PD-1 triple combination

The Missouri Mesothelioma Victims Center says, “We are urging a US Navy Veteran who has recently been diagnosed with mesothelioma anywhere in Missouri to call us anytime at 800-714-0303 about financial compensation as well as why it is incredibly vital to hire one of the nation’s most experienced mesothelioma attorneys.

RADiant treatment system at the American Society of Mohs Surgery annual meeting in Florida, which this year focuses on skin cancer.

This standard is used by clinical engineering teams around the globe to help guide them in how they run their medical equipment management programs.

The ceremony kicked off with a preview video on BIO 2019 and the Biotech Leaders that are heading to Philadelphia in June.